Anis John Kadado

Anis John Kadado

Auto-generated profile, based on publicly available information

Anis John Kadado

University of Massachusetts Chan Medical School - Baystate Regional Campus

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2019 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SASuheil Albert Atallah-Yunes
Suheil Albert Atallah-Yunes
AKAnis John Kadado
Anis John Kadado
GKGregory P. Kaufman
Gregory P. Kaufman
JHJaime Hernandez-Montfort
Jaime Hernandez-Montfort

8 July 2019 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
SLSeung Hee Lee
Seung Hee Lee
SLSuho Lee
Suho Lee
JDJing Du
Jing Du
KJKanika Jain
Kanika Jain
MDMin Ding
Min Ding
JHJohn Hwa
John Hwa
Mitophagy can selectively remove damaged toxic mitochondria, protecting a cell from apoptosis. The molecular spatial–temporal mechanisms governing autophagosomal selection of reactive oxygen species (ROS)‐damaged mitochondria, particularly in a platelet (no genomic DNA for transcriptional regulation), remain unclear. We now report that the mitochondrial matrix protein MsrB2 plays an important role in switching on mitophagy by reducing Parkin methionine oxidation (MetO), and transducing mitophagy through ubiquitination by Parkin and interacting with LC3. This biochemical signaling only occurs at damaged mitochondria where MsrB2 is released from the mitochondrial matrix. MsrB2 platelet‐specific knockout and in vivo peptide inhibition of the MsrB2/LC3 interaction lead to reduced mitophagy and increased platelet apoptosis. Pathophysiological importance is highlighted in human subjects, where increased MsrB2 expression in diabetes mellitus leads to increased platelet mitophagy, and in platelets from Parkinson's disease patients, where reduced MsrB2 expression is associated with reduced mitophagy. Moreover, Parkin mutations at Met192 are associated with Parkinson's disease, highlighting the structural sensitivity at the Met192 position. Release of the enzyme MsrB2 from damaged mitochondria, initiating autophagosome formation, represents a novel regulatory mechanism for oxidative stress‐induced mitophagy.

1 June 2019 in EBioMedicine
Verified
Journal Article
Open access
KJKanika Jain
Kanika Jain
TTTarun Tyagi
Tarun Tyagi
KPKanchi Patell
Kanchi Patell
YXYi Xie
Yi Xie
AKAnis John Kadado
Anis John Kadado
JHJohn Hwa
John Hwa
Aging is a complex physiological phenomenon, intricately associated with cardiovascular pathologies, where platelets play a central pathophysiological role. Although antiplatelets are commonly employed to prevent and treat major adverse cardiovascular events, aging associated intraplatelet changes remain largely unexplored. Platelets were studied in high cardiovascular risk patients (aged 40-100 years) comparing them to younger healthy subjects. This was followed by cross sectional and longitudinal mice studies. Flow cytometry, biochemical and molecular assays were used to study platelets comprehensively. CVD Patients were categorized in the age groups 40-59, 60-79, and 80-100 years. Progressive decline in platelet health was observed in the 40-79 years age cohort, marked by increase in oxidative stress, hyperactivation and apoptotic markers. Paradoxically, this was reversed in patients aged above 79 years and the improved platelet phenotype was associated with lower oxidative damage. The platelets from the very old (80-100 year) group were found to be preloaded with increased antioxidants, which also contributed to higher resistance against induced redox insults. Cross sectional mouse studies excluded the effect of comorbidities and medications. Longitudinal mouse studies implicate an adaptive increase in antioxidant levels as the mechanism. We report a novel age associated, non-linear redox regulation in platelets in both humans and mice. In advanced age, there occurs an adaptive increase in platelet antioxidants, reducing the intracellular ROS and leading to a healthier platelet phenotype. Clinically, our results advocate the use of less aggressive antiplatelet therapies for CVD in the elderly population. FUND: Study funded by NIH-NHLBI, RO1-HL122815 and RO1-HL115247.

1 January 2018 in Trends in Cardiovascular Medicine
Verified
Journal Article
Closed access
AKAnis J. Kadado
Anis J. Kadado
JAJoseph G. Akar
Joseph G. Akar
JHJames P. Hummel
James P. Hummel


1 October 2019 in Current Problems in Cancer
Verified
Journal Article
Closed access
SASuheil Albert Atallah-Yunes
Suheil Albert Atallah-Yunes
AKAnis John Kadado
Anis John Kadado
MSMyat Han Soe
Myat Han Soe